Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Caladrius Biosciences, Inc. (CLBS : NSDQ)

• Company Description    Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. Number of Employees: 27

• Price / Volume Information    Yesterday's Closing Price: $0.46 Daily Weekly Monthly 20 Day Moving Average: 784,342 shares Shares Outstanding: 60.52 (millions) Market Capitalization: $27.93 (millions) Beta: 1.10 52 Week High: $1.68 52 Week Low: $0.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -29.00% -20.04% 12 Week -35.57% -29.18% Year To Date -45.16% -33.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 110 ALLEN ROAD 2ND FLOOR - BASKING RIDGE,NJ 07920 USA ph: 908-842-0100 fax: 646-514-7787 jmenditto@caladrius.com http://www.caladrius.com

• General Corporate Information    Officers David J. Mazzo - Chief Executive Officer;President Gregory B. Brown - Chairman of the Board of Directors Michael H. Davidson - Director Cynthia L. Flowers - Director Steven S. Myers - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 128058203 SIC: 8090 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 60.52 Most Recent Split Date: 7.00 (0.10:1) Beta: 1.10 Market Capitalization: $27.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.40 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.32 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 63.16% vs. Previous Quarter: 36.36% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -24.66 12/31/21 - -27.12 09/30/21 - -30.23 ROA 03/31/22 - -23.65 12/31/21 - -25.99 09/30/21 - -28.86 Current Ratio 03/31/22 - 32.38 12/31/21 - 21.26 09/30/21 - 25.08 Quick Ratio 03/31/22 - - 12/31/21 - 21.27 09/30/21 - 25.08 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 1.46 12/31/21 - 1.54 09/30/21 - 1.65 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©